The report is titled as ‘Gaucher Disease Drugs Market: Opportunity Analysis and Future Assessment 2020-2028’. An overview of conceptual frameworks, analytical approaches of the gaucher disease drugs market is the main objective of the report, which further consists the market opportunity and insights of the data involved in the making of the respective market. Gaucher disease drugs market is expected to grow with significant rate in the near future.
The global gaucher disease drugs market in 2020 is estimated for more than US$ 1.2 Bn and expected to reach a value of US$ 1.4 Bn by 2028 with a significant CAGR of 1.5%.
Gaucher Disease Drugs Market Dynamics
Increasing demand for adequate treatment, rising incidence of the disease, and the efforts for identification of Gaucher diseased patients favors the market growth. In addition, the strong commercialization of enzyme replacement therapy based FDA approved drugs like Cerezyme, Vpriv, and Elelyso coupled with the growing government’s initiatives to promote the Gaucher disease awareness programs also boosts the growth of Gaucher disease drugs market. For instance, the launch of Gaucher Awareness day, by European Gaucher Alliance, to educate their citizens about this rare and curable disease.
Moreover, the strategic collaboration between European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) to promote the innovative approach to develop the cure for Gaucher disease is also benefitting the market growth.
Such collaborations for development and commercialization of therapeutics with higher number of FDA approved drugs in the ERT segments also boosts the demand for gaucher disease drug.
Additionally, the products in the pipeline, like LB-201, JR-101 also favors market growth. However, lack of awareness regarding the symptoms, diagnosis, and treatment of disease among rural population are anticipated to restrain growth of the global gaucher disease drugs market during the next decade.
On the other hand, the high cost associated with the treatment, lack of drugs in the late-stage pipeline and its rarity may restrain growth of the global market. Nevertheless, the high unmet need for the optimization and development of improved treatments to resolve neuronopathic complications at reasonable rates and appropriate administration schedule is likely to create opportunities for growth of the global market.
Gaucher Disease Drugs Market Segmentation
The global gaucher disease drugs market is segmented on the basis of type, therapy, and by region.
As per the National Gaucher Foundation, this disease can be treated with two currently available options, including enzyme replacement therapy and substrate reduction therapy. The enzyme replacement therapy can be accomplished with the usage of Cerezyme, VPRIV, and Elelyso FDA approved drugs.
Moreover, the substrate reduction therapy makes use of Cerdelga and Zavesca FDA approved drugs. However, the strategic collaborations among key players to optimize and develop the drug holds numerous products in pipeline, including LB-201 and LB-205 (by Lixte Biotechnology Holdings Inc.), JR-101 (by JCR Pharmaceuticals Co. Ltd.), A Phase II clinical trial of arimoclomol for Gaucher disease (by Orphazyme ApS), etc.
Key players operating in the global gaucher disease drugs market include Sanofi Genzyme, Shire Human Genetics Therapies, Inc., Pfizer, Inc., and Johnson & Johnson.
Regional Segmentation
On the basis of region, the gaucher disease drugs market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.
MMC Overview on Gaucher Disease Drugs Market Report
The non-identical approach of Meridian Market Consultants stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give better opportunity for the customers to put their effort.
A research report on the Gaucher Disease Drugs market by Meridian Market Consultants is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that supports market and the factors that are acting as impedance for the growth of the market.
Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market.
Factors that are benchmarked while estimating the market
Various factors that are benchmarked while estimating the market growth includes (but not restricted to):
• New product designs and launches
• Current product compliance
• Reimbursement
• Concerns for use of Gaucher Disease Drugs
• Advantage of Gaucher Disease Drugs over other Drugs
Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries globally for providing regional insights of the product segment in the report. This helps our clients to take informed decision.
A mix of top-down and bottom-up approach is followed to arrive and validate our market value estimations. For a product segment like wherein one/two manufacturer(s) dominates the market, it’s products sales, previous growth rates and market expansion plans are considered to generate market share in the global market.
1. Global Gaucher Disease Drugs Market Report Overview
1.1. Introduction
1.2. Report Description
1.3. Methodology
2. Global Gaucher Disease Drugs Market Overview
2.1. Introduction
2.1.1. Market Definition
2.1.2. Market Taxonomy
2.2. Executive Summary
2.3. Global Gaucher Disease Drugs Market Snapshot
2.4. Global Gaucher Disease Drugs Market Size and Forecast, 2020–2028
2.4.1. Introduction
2.4.2. Market Value Forecast and Annual Growth Rate (AGR) Comparison (2020–2028)
2.5. Global Gaucher Disease Drugs Market Dynamics
2.5.1. Drivers
2.5.2. Restraints
2.5.3. Opportunity
2.5.4. Trends
2.6. Key Regulations
2.7. Porter’s Five Forces Model
3. Global Gaucher Disease Drugs Market, By Type
3.1. Introduction
3.1.1. Annual Growth Rate Comparison, By Type
3.1.2. BPS Analysis, By Type
3.2. Market Revenue (US$Mn) Forecast, By Type
3.2.1. Type 1
3.2.2. Type 2
3.2.3. Type 3
3.3. Global Gaucher Disease Drugs Market Attractiveness Index, By Type
4. Global Gaucher Disease Drugs Market, By Therapy
4.1. Introduction
4.1.1. Annual Growth Rate Comparison, By Therapy
4.1.2. BPS Analysis, By Therapy
4.2. Market Revenue (US$Mn) Forecast, By Therapy
4.2.1. Enzyme Replacement Therapy
4.2.2. Substrate Replacement Therapy
5. Global Gaucher Disease Drugs Market, By Region
5.1. Introduction
5.1.1. Annual Growth Rate Comparison, By Region
5.1.2. BPS Analysis, By Region
5.2. Market Revenue (US$Mn) Forecast, By Region
5.2.1. North America
5.2.2. Latin America
5.2.3. Europe
5.2.4. Asia Pacific
5.2.5. Middle East
5.2.6. Africa
5.3. Global Gaucher Disease Drugs Market Attractiveness Index, By Region
6. North America Gaucher Disease Drugs Market Analysis and Forecast, 2020–2028
6.1. Introduction
6.1.1. Annual Growth Rate Comparison, By Country
6.1.2. BPS Analysis, By Country
6.2. Market Revenue (US$Mn) Forecast, By Country
6.2.1. U.S. Gaucher Disease Drugs Market
6.2.2. Canada Gaucher Disease Drugs Market
6.3. North America Gaucher Disease Drugs Market, By Type
6.3.1. Type 1
6.3.2. Type 2
6.3.3. Type 3
6.4. North America Gaucher Disease Drugs Market, By Therapy
6.4.1. Enzyme Replacement Therapy
6.4.2. Substrate Replacement Therapy
6.5. North America Gaucher Disease Drugs Market Attractiveness Index
6.5.1. By Country
6.5.2. By Type
6.5.3. By Therapy
7. Latin America Gaucher Disease Drugs Market Analysis and Forecast, 2020–2028
7.1. Introduction
7.1.1. Annual Growth Rate Comparison, By Country
7.1.2. BPS Analysis, By Country
7.2. Market (US$Mn) Forecast, By Country
7.2.1. Brazil Gaucher Disease Drugs Market
7.2.2. Mexico Gaucher Disease Drugs Market
7.2.3. Argentina Gaucher Disease Drugs Market
7.2.4. Rest Of Latin America Gaucher Disease Drugs Market
7.3. Latin America Gaucher Disease Drugs Market, By Type
7.3.1. Type 1
7.3.2. Type 2
7.3.3. Type 3
7.4. Latin America Gaucher Disease Drugs Market, By Therapy
7.4.1. Enzyme Replacement Therapy
7.4.2. Substrate Replacement Therapy
7.5. Attractiveness Index
7.5.1. By Country
7.5.2. By Type
7.5.3. By Therapy
8. Europe Gaucher Disease Drugs Market Analysis and Forecast, 2020–2028
8.1. Introduction
8.1.1. Annual Growth Rate Comparison, By Country
8.1.2. BPS Analysis, By Country
8.2. Market (US$Mn) Forecast, By Country
8.2.1. U.K. Gaucher Disease Drugs Market
8.2.2. Germany Gaucher Disease Drugs Market
8.2.3. Italy Gaucher Disease Drugs Market
8.2.4. France Gaucher Disease Drugs Market
8.2.5. Spain Gaucher Disease Drugs Market
8.2.6. Russia Gaucher Disease Drugs Market
8.2.7. Poland Gaucher Disease Drugs Market
8.2.8. BENELUX Gaucher Disease Drugs Market
8.2.9. NORDIC Gaucher Disease Drugs Market
8.2.10. Rest of Europe Gaucher Disease Drugs Market
8.3. Europe Gaucher Disease Drugs Market, By Type
8.3.1. Type 1
8.3.2. Type 2
8.3.3. Type 3
8.4. Europe Gaucher Disease Drugs Market, By Therapy
8.4.1. Enzyme Replacement Therapy
8.4.2. Substrate Replacement Therapy
8.5. Europe Gaucher Disease Drugs Market Attractiveness Index
8.5.1. By Country
8.5.2. By Type
8.5.3. By Therapy
9. Asia Pacific Gaucher Disease Drugs Market Analysis and Forecast, 2020–2028
9.1. Introduction
9.1.1. Annual Growth Rate Comparison, By Country
9.1.2. BPS Analysis, By Country
9.2. Market (US$Mn) Forecast, By Country
9.2.1. China Gaucher Disease Drugs Market
9.2.2. India Gaucher Disease Drugs Market
9.2.3. Japan Gaucher Disease Drugs Market
9.2.4. Australia and New Zealand Gaucher Disease Drugs Market
9.2.5. South Korea Gaucher Disease Drugs Market
9.2.6. ASEAN Gaucher Disease Drugs Market
9.2.7. Rest of Asia Pacific Gaucher Disease Drugs Market
9.3. Asia Pacific Gaucher Disease Drugs Market, By Type
9.3.1. Type 1
9.3.2. Type 2
9.3.3. Type 3
9.4. Asia Pacific Gaucher Disease Drugs Market, By Therapy
9.4.1. Enzyme Replacement Therapy
9.4.2. Substrate Replacement Therapy
9.5. Asia Pacific Gaucher Disease Drugs Market Attractiveness Index
9.5.1. By Country
9.5.2. By Type
9.5.3. By Therapy
10. Middle East Gaucher Disease Drugs Market, By Region
10.1. Introduction
10.1.1. Annual Growth Rate Comparison, By Country
10.1.2. BPS Analysis, By Country
10.2. Market (US$Mn) Forecast, By Country
10.2.1. GCC Countries Gaucher Disease Drugs Market
10.2.2. Israel Gaucher Disease Drugs Market
10.2.3. Oman Gaucher Disease Drugs Market
10.2.4. Rest of Middle East Gaucher Disease Drugs Market
10.3. Middle East Gaucher Disease Drugs Market, By Type
10.3.1. Type 1
10.3.2. Type 2
10.3.3. Type 3
10.4. Middle East Gaucher Disease Drugs Market, By Therapy
10.4.1. Enzyme Replacement Therapy
10.4.2. Substrate Replacement Therapy
10.5. Middle East Gaucher Disease Drugs Market Attractiveness Index
10.5.1. By Country
10.5.2. By Type
10.5.3. By Therapy
11. Africa Gaucher Disease Drugs Market, By Region
11.1. Introduction
11.1.1. Annual Growth Rate Comparison, By Country
11.1.2. BPS Analysis, By Country
11.2. Market (US$Mn) Forecast, By Country
11.2.1. South Africa Gaucher Disease Drugs Market
11.2.2. Egypt Gaucher Disease Drugs Market
11.2.3. North Africa Gaucher Disease Drugs Market
11.2.4. Rest of Africa Gaucher Disease Drugs Market
11.3. Africa Gaucher Disease Drugs Market, By Type
11.3.1. Type 1
11.3.2. Type 2
11.3.3. Type 3
11.4. Africa Gaucher Disease Drugs Market, By Therapy
11.4.1. Enzyme Replacement Therapy
11.4.2. Substrate Replacement Therapy
11.5. Africa Gaucher Disease Drugs Market Attractiveness Index
11.5.1. By Country
11.5.2. By Type
11.5.3. By Therapy
12. Recommendation
12.1. Market Strategy
13. Competitive Landscape
13.1. Competition Dashboard
13.2. List and Company Overview of Global Key Players
13.3. Company Profiles
13.3.1. Sanofi Genzyme
13.3.1.1. Company Overview
13.3.1.2. Financial Overview
13.3.1.3. Product Portfolio
13.3.1.4. Key Developments
13.3.1.5. Business Strategies
13.3.2. Shire Human Genetics Therapies, Inc.
13.3.3. Pfizer, Inc.
13.3.4. Johnson & Johnson
14. Acronyms
Frequently Asked Questions
What is the projected market size & Compound Annual Growth Rate (CAGR) of the market?
The global gaucher disease drugs market in 2020 is estimated for more than US$ 1.2 Bn and expected to reach a value of US$ 1.4 Bn by 2028 with a significant CAGR of 1.5%.
What are the key factors driving the growth of market?
Increasing demand for adequate treatment, rising incidence of the disease, and the efforts for identification of Gaucher diseased patients favors the market growth. In addition, the strong commercialization of enzyme replacement therapy based FDA approved drugs like Cerezyme, Vpriv, and Elelyso coupled with the growing government’s initiatives to promote the Gaucher disease awareness programs also boosts the growth of Gaucher disease drugs market.
What segments are covered in market report?
The global gaucher disease drugs market is segmented on the basis of type, therapy, and by region.
What are the key participating players in the market?
Key players operating in the global gaucher disease drugs market include Sanofi Genzyme, Shire Human Genetics Therapies, Inc., Pfizer, Inc., and Johnson & Johnson.
